Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration

Ruin Moaddel1, Panos Zanos2,3,7, Cristan A. Farmer4,7, Bashkim Kadriu4, Patrick J. Morris5, Jacqueline Lovett1, Elia E. Acevedo-Diaz4, Grace W. Cavanaugh4, Peixiong Yuan4, Mani Yavi4, Craig J. Thomas5, Lawrence T. Park6, Luigi Ferrucci1, Todd D. Gould5,6 and Carlos A. Zarate Jr4

This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022

Subanesthetic-dose racemic (R,S)-ketamine (ketamine) produces rapid, robust, and sustained antidepressant effects in major depressive disorder (MDD) and bipolar disorder (BD) and has also been shown to effectively treat neuropathic pain, complex regional pain syndrome, and post-traumatic stress disorder (PTSD). However, to date, its mechanism of action remains unclear. Preclinical studies found that (2R,6R;2S,6S)-hydroxynorketamine (HNK), a major circulating metabolite of ketamine, elicits antidepressant effects similar to those of ketamine. To help determine how (2R,6R)-HNK contributes to ketamine’s mechanism of action, an exploratory, targeted, metabolomic analysis was carried out on plasma and CSF of nine healthy volunteers receiving a 40-minute ketamine infusion (0.5 mg/kg). A parallel targeted metabolomic analysis in plasma, hippocampus, and hypothalamus was carried out in mice receiving either 10 mg/kg of ketamine, 10 mg/kg of (2R,6R)-HNK, or saline. Ketamine and (2R,6R)-HNK both affected multiple pathways associated with inflammatory conditions. In addition, several changes were unique to either the healthy human volunteers and/or the mouse arm of the study, indicating that different pathways may be differentially involved in ketamine’s effects in mice and humans. Mechanisms of action found to consistently underlie the effects of ketamine and/or (2R,6R)-HNK across both the human metabolome in plasma and CSF and the mouse arm of the study included LAT1, IDO1, NAD+, the nitric oxide (NO) signaling pathway, and sphingolipid rheostat.

Translational Psychiatry (2022) 12:179; https://doi.org/10.1038/s41398-022-01941-x

INTRODUCTION

Racemic (R,S)-ketamine (ketamine) has been in use since 1970 as a rapid-acting anesthetic [1] and has been listed on the WHO’s essential medicine list since 1985. Recent studies found that a single, subanesthetic-dose ketamine infusion produced rapid and sustained antidepressant effects in individuals with major depressive disorder (MDD) [2, 3] and bipolar depression (BD) [4]. Ketamine also appears to effectively treat neuropathic pain [5], complex regional pain syndrome [6, 7], pre-and post-operative pain [8], and post-traumatic stress disorder (PTSD) [9, 10], in addition to having analgesic [11] and anti-inflammatory effects [8, 12].

Despite this promising treatment profile, subanesthetic-dose ketamine has adverse effects including dissociation, cognitive impairment, and psychotomimetic effects, as well as significant abuse liability [13–15]. These adverse effects have been attributed to N-methyl-D-aspartate receptor (NMDAR) inhibition, a mechanism of action proposed to underlie ketamine’s antidepressant effects [16]. Nevertheless, several other NMDAR antagonists do not elicit a similar antidepressant pharmacological response [17], suggesting that other mechanisms underlie ketamine’s rapid antidepressant properties [15]. As a result, ketamine’s precise antidepressant/analgesic mechanism of action remains largely unknown. Other proposed mechanisms include: blockage of the hyperpolarization-activated cyclic nucleotide gated potassium channel 1 (HCN1) [18]; involvement of the cholinergic, aminergic, and opioidergic systems [18]; increased mitochondrial activity, synaptogenesis and mammalian target of rapamycin (mTOR) signaling pathways; inhibitors of group II mGlu receptors [19]; and protein synthesis via eukaryotic elongation factor-2 (eEF2) kinase inhibition [20, 21].

In this context, one alternative mechanism that may underlie ketamine’s antidepressant effects is related to its metabolites. Ketamine is extensively metabolized to a large number of downstream metabolites including norketamine, dehydronorke-tamine, hydroxyketamines, and hydroxynorketamines (HNKs) [4, 7, 15]. In particular, (2S,6S;2R,6R)-HNK was found post-ketamine administration in the plasma of human participants following antidepressant-dose ketamine administration.
[4, 7, 22] as well as in the brain and plasma of mice [23]. In rodent models, (2R,6R)-HNK was subsequently found to elicit antidepressant-like effects similar to those of ketamine but without its adverse effects [21, 23–31]. (2R,6R)-HNK was also found to induce analgesic effects in preclinical models of pain [32]. In terms of potential mechanisms of action, both ketamine and (2R,6R)-HNK upregulated α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors in vivo [23] but, when compared directly, only (2R,6R)-HNK upregulated AMPA receptors in vitro [33]. Deciphering the exact mechanism of both ketamine’s and (2R,6R)-HNK’s antidepressant activity remains a major priority in the field.

Metabolomics provides a comprehensive analysis of lipids, amino acids, biogenic amines, and other metabolic products within a given biological subject [34]. Thus, determining metabolite changes in cerebrospinal fluid (CSF) post-ketamine administration may capture a metabolic signal that is closer to ketamine’s mechanism of action, thereby helping identify its effects on the central nervous system (CNS). To date, most metabolomic studies with ketamine have been limited to using plasma from humans and/or rodents [35–37]. This exploratory study was a targeted metabolomic analysis carried out on the plasma and CSF of healthy human participants who received a 40 min intravenous infusion of ketamine (0.5 mg/kg) to determine whether changes in the plasma corresponded to similar changes in the CSF. Several specific metabolomes were also targeted that have been shown to play a role in depression and/or neurodegenerative diseases, including the kynurenine (KYN) [35] and nicotinamide adenine dinucleotide (NAD)+ metabolomes [38–40]. To help determine the contribution of (2R,6R)-HNK to changes in the metabolomic profile observed following ketamine treatment, a parallel targeted metabolomic analysis was carried out in mice that received either 10 mg/kg ketamine, 10 mg/kg of (2R,6R)-HNK, or saline; the mouse metabolomic analysis was carried out in plasma, hippocampus, and hypothalamus.

**MATERIALS AND METHODS**

**Human participants**

Nine healthy human volunteers aged 19–36 years (mean age = 27 ± 6) (Supplementary Table S1) participated in the study. Healthy control subjects consisted of mixed sexes, with no Axis I disorder as determined by SCID-NP. Healthy control subjects were free of medications affecting neuronal function or cerebral blood flow or metabolism. Subjects in both groups were in good physical health as determined by medical history, physical exam, blood labs, electrocardiogram, chest x-ray, urinalysis, and toxicology. Healthy volunteers received a ketamine infusion (0.5 mg/kg/40 min IV) (Mylan Institutional, Galway, Ireland) and contributed plasma and CSF samples for up to 28 h. Blood and CSF were collected at baseline, 40 min, 120 min, and 230 min, as well as at 6, 10, 12, 22, 24, 26, and 28 h post-infusion. Parallel blood draws with a 48 h timepoint were also collected for mice. Time points were concentrated at 40 min as change from baseline. Based on the results of those analyses, individual analytes were selected and underwent univariate analysis, using the parameter estimates of interest were the estimated marginal means at each timepoint, given that Pareto scaling allows interpretation of the results based on the results of those analyses, individual analytes were selected and underwent univariate analysis, using the same model.

**Mouse**

Male CD-1 mice nine weeks of age received a single intraperitoneal (i.p.) (10 ml/kg) injection of saline, 10 mg/kg of ketamine hydrochloride, or 10 mg/kg of (2R,6R)-HNK hydrochloride. Samples were collected in EDTA-containing Eppendorf tubes, on ice. Concomitantly, the hippocampus and hypothalamus were excised using a mouse-brain matrix on ice. 100 µl of whole blood was also collected in a separate tube. All samples were frozen on dry ice immediately after collection. Eight samples were collected for each timepoint and treatment. All experimental procedures were approved by the University of Maryland Baltimore Animal Care and Use Committee and were conducted in full accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

**Metabolomics panels**

**Metabolomic assay.** A targeted metabolic assessment was carried out following the manufacturer’s protocol using Biocrates’ MxP Quant 500 kit (Biocrates, Innsbruck, Austria), which quantifies 630 distinct metabolites in human and rodent plasma (10 µl), human CSF (10 µl), and mouse brain (10 µl). For the mouse hypothalamus and hippocampus, tissue was homogenized following a previously published protocol [41] with slight modifications. Additional details can be found in the Supplementary Materials.

**Kynurenine metabolome.** Separation of the kynurenines (KYNs) was accomplished as previously described [35, 42]. Relative concentrations of the metabolites were determined in standard solution using area ratios calculated using a deuterated standard; because matrix effects were not considered, these only provide a measure of relative abundance and not absolute quantification. All data were normalized to a pooled sample of study participants that was run each day.

**NAD+ metabolome.** Separation of the NAD+ metabolites was accomplished as previously described [38, 39]; additional details can be found in the Supplementary Materials. Briefly, relative values for the metabolites were determined using area ratios of the targeted metabolites, and the corresponding internal standard and data were normalized to the pooled samples.

**Statistical analysis**

Because this was an exploratory analysis, no a priori power calculations were performed. Following guidelines established by the American Statistical Association [43], uncorrected p-values for two-tailed tests focusing on the magnitude and variability (confidence intervals) in effects are reported. Test assumptions were confirmed via visual inspection. Parameter estimates, test statistics, and uncorrected p-values for all comparisons are provided in the Supplementary Materials.

**Human data.** Data were log transformed prior to analysis. Values were Pareto-scaled to baseline. A principal components analysis (PCA) was performed on the Pareto-scaled data to reduce the number of features in the data, using the prcomp package for R version 4.0.2. The number of components was selected using a combination of eigenvalues > 1 and visual inspection of the scree plot. The effect of time (human) on the component scores was examined and, to account for repeated observations, a random subject intercept in a generalized linear model was used. The parameter estimates of interest were the estimated marginal means at each timepoint, given that Pareto scaling allows interpretation of these values as change from baseline. Based on the results of those analyses, individual analytes were selected and underwent univariate analysis, using the same model.

**Mouse data.** Data were log transformed prior to analysis. Area under the curve (AUC) for serial sacrifice design was calculated using the PK package for R version 4.0.2 [44]. The AUC of each metabolite was compared between groups using a Z-transformation. The NAD+ metabolome, comprising only a few features, was investigated using univariate analysis, wherein concentrations were Pareto-scaled to the control group and evaluated using a general linear model with fixed effects of time and group. The parameter estimates of interest were the between-group contrasts at each timepoint.

**RESULTS**

**Metabolomic analysis in healthy human volunteers**

Of the 630 potential metabolites quantified in the targeted metabolomic analysis of plasma and CSF samples from nine human volunteers, metabolites that had quantitative values in
less than 67% of the total samples were excluded, leaving 466 metabolites in the plasma and 82 in the CSF. Circulating NAD$^+$ levels in the CSF were also determined. In the PCA carried out with the metabolomic dataset and based on the scree plot, four components in CSF and seven components in plasma were carried forward, which explained 57% and 76% of the variance, respectively. The metabolites with the strongest loadings for each of these components are shown in Supplementary Fig. S1 and Supplementary Table S2. Only one component for plasma and CSF, PC2, exhibited a consistent pattern of change over time post-ketamine, where it steadily increased followed by a decrease by 28 h in the CSF and 48 h in plasma (Supplementary Fig. S1).

**Plasma metabolomics**

In the plasma compartment, the major contributors to the PC2 were bile acids, leucine, isoleucine, glycine, phenylalanine, methionine, cystine, 3-Met-His, and betaine, all of which loaded positively with PC2 (Fig. 1; Supplementary Table S2A). In the univariate analysis (Supplementary Table S3), all seven identified bile acids followed a similar pattern, with a steady increase at 40 min post-infusion that peaked at six hours, then decreased until 12 h, and returned to baseline at 48 h. The amino acids followed the same general pattern, with circulating levels near baseline for between two to four hours post-infusion, followed by increasing circulating levels peaking at 10 h (phenylalanine and methionine) or 12 h (leucine and isoleucine), then remaining steady before decreasing; levels had not returned to baseline at 48 h post-infusion. Of the ratios calculated, only the KYN/trypophan ratio decreased with ketamine treatment. Branch chain amino acid (BCAA) (sum of leucine, isoleucine, and valine) levels increased following ketamine treatment, and the arginine/asymmetric dimethylarginine (ADMA) ratio trended higher following ketamine treatment. Acetylcarnitine (C2), identified as one of the major contributors to the PC2, decreased two hours post-infusion, remained steady for the rest of the study, and did not return to baseline after 48 h.

Of the lipids, lysophosphatidylcholine (LPC) a C18:2 and LPC a C18:1 were observed post-ketamine, with a maximal decrease four hours post-infusion that did not return to baseline for 48 h. SM C18:1 also had a decreasing trend post-ketamine. Increasing levels of several diacylglycerols (DGs) and triglycerides (TGs) containing FA 18:2 were also observed (Supplementary Table S3). Several TGs were found to be major contributors to PC2 (Fig. 1; Supplementary Tables S2 and S3).

**CSF of human healthy controls**

In the CSF, amino acids, amino acid-related metabolites, sphingomyelins, and phosphatidylcholines were the major contributors that changed post-infusion (Fig. 1; Supplementary Tables S2B and S4). The bile acids measured in the CSF were either below or at the lower limit of quantitation. No LPC was detectable in more than 50% of the samples in the CSF, and no TGs were detectable in the CSF. NAD$^+$ levels decreased subtly in the CSF post-ketamine, then steadily decreased with a maximal drop at 22 h, finally returning near baseline at 26 h. In the univariate analysis (Supplementary Table S4), creatinine steadily increased post-infusion, and SM C16:0, SM C18:0, and SM C18:1 trended positively post-ketamine, peaking near 12 h post-infusion, remaining steady, and not returning to baseline 28 h post-infusion. PCaa C32:1, PCaa C34:1, and PCaa C36:1 also increased, peaking at 24 h. Tryptophan decreased post-ketamine in a biphasic manner, with a steady decrease until six hours, a moderate recovery returning to a steady, and not returning to baseline up to 28 hours. Symmetric dimethylarginine (SDMA), an endogenous inhibitor of nitric oxide synthase (NOS), had a negative association with ketamine treatment in the CSF, and the arginine/SDMA ratio, which reflects nitric oxide (NO) production, increased post-ketamine. However, the global arginine bioavailability ratio (GABR), a measure that estimates NO synthetic capacity in vivo [35], was not associated with ketamine treatment. Of the remaining ratios, BCAAs decreased post-ketamine. The putrescine/ornithine ratio initially increased, then decreased six hours post-infusion, and did not return to baseline until 28 h post-infusion. Interestingly, several metabolites loaded in opposite directions onto the plasma and CSF components post-ketamine, including leucine [0.09/−0.09], isoleucine [0.11/−0.09], tryptophan [0.02/−0.25], methionine [0.12/−0.10], and tyrosine [0.07/−0.07], which loaded positively on plasma and negatively on CSF, respectively, suggesting decreased transport into the CSF post-ketamine.

**Metabolomic analysis in mice**

Of the 630 metabolites investigated with the MxP 500 platform, 337 were above the limit of detection in >67% of the mouse plasma samples available for data analysis. Similar results were found for 185 metabolites in the hypothalamus and 96 metabolites in the hippocampus. The AUC calculated for serial sacrificed design of each metabolite was compared using a Z-transformation between groups receiving 10 mg/kg ketamine, 10 mg/kg (2 R,6 R)-HNK, and saline in mouse plasma (Supplementary Table S5), mouse hippocampus (Supplementary Table S6), and hypothalamus (Supplementary Table S7). Test statistics (2) for the group comparison are plotted for features with at least one -log(p) > 2 (Fig. 2).
Plasma metabolomics

The results of the univariate metabolomic analysis in mice revealed that four metabolites changed following treatment with either ketamine or (2R,6R)-HNK, with tryptophan decreasing following treatment and three PCs (PC ae C42:5, PC aa C42:6, PC ae C42:0) increasing following treatment (Fig. 2; Supplementary Table S5). From the NAD\(^+\) metabolites (Supplementary Table S8), only NADP\(^+\) and NADPH changed in both ketamine and (2R,6R)-HNK treated mice, with NADP\(^+\) decreasing at 15 min post-treatment and NADPH decreasing at 15 and 60 min post-treatment.

In (2R,6R)-HNK treated mice, serotonin, three PCs (PC aa C40:3, PC aa C40:4, PC aa C42:4) and SM C24:0 increased following treatment, with sarcosine, valine, isoleucine, and four TGs (TG (16:0_40:8), TG (18:0_38:6), TG(20:3_34:0), TG(22:6_32:0)) decreasing post-treatment (Fig. 2; Supplementary Table S5). From the NAD\(^+\) metabolites (Supplementary Table S8), only NAD\(^+\) decreased slightly at 15 min post-treatment (2R,6R)-HNK treatment. The nicotinamide mononucleotide (NMN): nicotinamide (NAM) ratio, an indication of nicotinamide phosphoribosyltransferase (NAMPT) activity, decreased at 15 minutes in (2R,6R)-HNK-treated mice.

In ketamine-treated mice, glutamate and aspartate decreased post-treatment (Fig. 2, Supplementary Table S5), and PAG, PC ae C38:1, PC ae C38:3, three TGs (TG (16:0_32:3) TG(17:1_34:2), TG (20:3_36:5)), ceramide (Cer) (d18:1/23:0), and cholesterol ester (CE) (18:1, CE 20:5, and CE 16:1 increased post-ketamine. For the NAD\(^+\) metabolites, NAM increased slightly at 24 h post-ketamine (Supplementary Table S8). Although, no ratios were found to change following ketamine treatment, at 240 min NAD\(^+\) kinase (NADP/NAD\(^+\)) was higher in (2R,6R)-HNK-treated mice relative to ketamine-treated mice, and NMMAT (NAD\(^+\)/NMN) were higher in ketamine-treated mice relative to (2R,6R)-HNK-treated mice.

Hippocampus and hypothalamus

Univariate analyses found that only Hex Cer (d18:1/24:0) increased in the hippocampus (-log(p) > 2) following both ketamine and (2R,6R)-HNK treatment. No other metabolites were found to change following (2R,6R)-HNK treatment in the hippocampus. However, several additional metabolites decreased following ketamine treatment, including asparagine, α-Amino adipic acid (α-AAA), α-amino butyric acid (AABA), tryptophan, proline, serotonin, threonine, leucine, methionine, glutamic and γC2 (Fig. 2; Supplementary Table S6); in addition, several ceramides (Cer (d18:1/24:1), Cer (d18:1/24:0), HexCer (d18:1/18:0), HexCer (d18:1/20:0), Hex Cer (d18:1/22:0)) increased post-ketamine.

In the hypothalamus, univariate analysis found that LPC a C26:1 increased and PC ae C36:5 decreased in both ketamine and (2R,6R)-HNK treatment (Fig. 2; Supplementary Table S7). Two additional metabolites decreased following (2R,6R)-HNK treatment: valine and PC ae C36:6. In ketamine-treated mice, phenylalanine, histidine, glycine, cystine, deoxycholic acid (DCA), serine, trigonelline, and LPC a C18:1 increased post-treatment.

DISCUSSION

This longitudinal study used metabolomics to explore the putative mechanisms underlying ketamine’s therapeutic effects while also assessing the relative metabolomic differences between (2R,6R)-HNK and ketamine to provide insights into their respective mechanisms of action. The targeted metabolomic study was carried out in the plasma and CSF of nine healthy human volunteers who received a 40 min ketamine infusion (0.5 mg/kg), and a parallel targeted study was carried out in plasma, hippocampus, and hypothalamus of mice receiving either 10 mg/kg of ketamine, 10 mg/kg of (2R,6R)-HNK, or saline. Ketamine and (2R,6R)-HNK metabolomic changes were shown to affect multiple pathways, several of which are associated with inflammation (Fig. 3).

Several studies have suggested that ketamine’s antidepressant effects are mediated via the mTOR signaling pathway [45, 46], and pre-clinical evidence also suggests that (2R,6R)-HNK exerts mTOR-dependent effects [21, 26, 29–31]. Ketamine-induced mTOR activation has been associated with a short-term decrease in depressive symptoms in MDD patients, and this activation may be...
due to increased circulating levels of BCAAs [47]. In this context, in the present study BCAAs increased in the plasma of healthy volunteers post-ketamine but decreased in the CSF, echoing similar findings in both the hippocampus and hypothalamus of ketamine- and (2 R,6 R)-HNK-treated mice, respectively. Whether the decrease in the CSF reflects a decrease in mTORC1 activation is unknown, given that circulating CSF metabolite levels reflect the extracellular environment and may not accurately reflect intracellu- lar changes, which may increase as a result of intracellular compensatory mechanisms. Tryptophan, phenylalanine, and arginine were also found to decrease in CSF following ketamine treatment, with tryptophan also decreasing in the hippocampus of ketamine-treated mice. These amino acids are all substrates for the large neutral amino acid (LAT-1) (SLC7A5) transporter [48], suggesting that ketamine may induce decreased transport across the blood-brain barrier via LAT-1. This would be consistent with a recent study showing that leucine induced antidepressant-like effects by blocking KYN uptake via LAT-1 in a mouse model of LPS-induced depressive-like behaviors [49].

KYN is metabolized to several metabolites involved in the interface of inflammatory/immune response and glutamatergic neurotransmission [50]. IDO1, a therapeutic target in depression, metabolizes tryptophan to KYN and is upregulated during pro-inflammatory states induced by several cytokines (IL-1β, IL-6, IFN-γ, TNF-α) [51, 52]. In this study, the KYN/tryptophan ratios, a marker of IDO activity, decreased in the plasma of healthy volunteers post-ketamine, consistent with ketamine’s anti-inflammatory effects. The KYN pathway is also the de novo synthetic pathway for NAD⁺, an important cofactor for several inflammatory-related disease in animal models [59]. In the mouse arm of the study, NAMPT activity decreased in (2 R,6 R)-HNK-treated mice and showed a trend towards increasing in (2 R,6 R)-HNK-treated mice at several timepoints. Notably, increased NAM levels are thought to have beneficial anti-inflammatory [60] and antidepressant [60, 61] effects.

Although, the signaling molecule NO has also been thought to play a role in inflammation as well as in ketamine’s antidepressant effects [35, 62], a recent study suggested that the NO pathway may not play a primary role in these effects [63]. Multiple factors affect NO levels, including arginase activity, amino acid levels, NOS activity, and the presence of specific endogenous NOS inhibitors, such as ADMA and/or SDMA [34]. GABR, an estimate of NO synthetic capacity in vivo, was previously demonstrated to increase in plasma following ketamine treatment in MDD responders relative to non-responders [34], with no change in healthy volunteers. In this study, GABR did not change in the plasma or CSF of healthy volunteers post-ketamine. However, the arginine/SDMA ratio and the arginine/ADMA ratio, which reflects NO production, were both increased in human CSF and plasma. This is consistent with previous reports showing that the selective serotonin reuptake inhibitor (SSRI) paroxetine increases circulating NO levels in healthy volunteers [64] and suggests that ketamine may act through the NO cycle via the bioavailability of arginine.

Ketamine also increased levels of several bile acids in the plasma of healthy volunteers (Fig. 1), suggesting that cholesterol metabolism may play a role in this agent’s mechanism of action [65]. A recent study found that lower serum bile acid concentrations were associated with markers of dementia, suggesting that cholesterol catabolism and bile acid synthesis may impact the progression of dementia [66]. Several receptors are activated by...
the bile acids, including the nuclear receptors FXR, PXR, and vitamin D3 receptor, as well as membrane receptors such as Takeda G-protein-coupled receptor 5 (TGR5) and sphingosine-1-phosphate receptor 2 (SIPR2) [67, 68]. TGR5 activation induces key anti-inflammatory pathways [67] and, as a result, may play a role in ketamine’s antidepressant effects. NMDA and GABA<sub>A</sub>-R are also well-studied bile acid-regulated receptors in the brain, where they were shown to function as NMDAR and GABA<sub>A</sub>-R antagonists [67], and chenodeoxycholic acid (CDCA) and taurochenodeoxycholic acid (TCDDA) are the most effective at reducing the activation of these receptors [67]. CDCA and TCDCA also preferentially inhibit GluN2D and GluN3B containing NMDARs, followed by GluN2A- and GluN2B-containing NMDARs [69]. While high circulating cholesterol is a risk factor for dementia in young and middle-aged individuals, whether peripheral cholesterol levels directly impact brain function remains unknown [70]. However, considering that cholesterol homeostasis is carried out by the same protein network in the CNS as in the liver [71], and that ketamine and its metabolites cross the blood-brain barrier [23, 26, 29, 72], a potentially similar increase in the CSF could be expected. This is consistent with a recent study that implicated Takeda G-protein-coupled receptor 5 (TGR5) in the mechanism of antidepressant efficacy, including for ketamine [73]. Interestingly, TRKB signaling is bidirectionally linked to brain cholesterol metabolism [73]. In our study, none of the bile acids were found at quantitative levels in the CSF, but DCA increased post-ketamine in mouse hypothalamus.

Conjugated bile acids activate the extracellular regulated protein kinase (ERK1/2) and protein kinase B (Akt) signaling pathways via the sphingosine-1-phosphate receptor (SIPR2) [74]. The SIPR2 is expressed in hippocampal pyramidal/granular neurons, and mice lacking this receptor have a high rate of spontaneous seizures and cognitive deficits [75]. SIPR2 activation is a key regulator of sphingosine kinase 2 (Sphk2) [74], which phosphorylates sphingosine to sphingosine-1-phosphate, resulting in increased levels of DBNF and neurogenesis [76]. In this study, healthy volunteers receiving ketamine had increased CSF concentrations of SM 18:0, SM18:1, SM 16:0, and SM 24:1. Increases in SMs would likely be beneficial, given that lower circulating levels of SM have been reported in MDD patients [77], and circulating levels of SM C18:1 were increased in MDD patients post-ketamine [35]. In mouse plasma, only SM C24:0 was increased in (2,6,8)-HNK-treated mice. A similar increase in SMC24:0 was also observed following treatment with the SSRI s citalopram and escitalopram [78]. This increase may also have resulted from an indirect and/or direct effect on acid sphingomyelinase activity, which catalyzes the degradation of sphingomyelin to phosphocholine and ceramide [35]. In contrast, Cer (d18:1:23:0) increased in the plasma of ketamine-treated mice, with Hex Cer (d18:1:24:0) increasing in the hippocampus of both (2,6,8)-HNK and ketamine-treated mice, and HexCer (d18:1:18:0), Cer (d18:1:24:1), Hex Cer (d18:1:20:0), and Hex Cer (d18:1:22:0) increasing in the hippocampus of ketamine-treated mice. While these findings are unexpected, previous studies also found that patients treated with antidepressants had higher ceramide levels than patients not taking these drugs [79]. The results suggest that ketamine plays a role in the “sphingolipid-rheostat” [35, 80]. Notably, changes in the sphingolipid/ceramide profile can alter the organization of specific lipid microdomains, resulting in brain function changes [81].

Lipids carry out a variety of functions, including membrane formation and trafficking, storing energy, neuronal signaling and survival, sub-compartmentalizing cell membranes, forming functional platforms that operate in signaling, acting as second messengers in signal transduction, and regulating glucocorticoid action as well as inflammatory processes [82]. In this study, several LPCs increased in the plasma of healthy volunteers post-ketamine, including LPC a C18:2, which at low circulating levels has been linked to impaired glucose tolerance, insulin resistance, type 2 diabetes, memory impairment, and coronary heart disease [83]. Similar increases were found in mouse hypothalamus in both ketamine- and (2,6,8)-HNK-treated mice, including increased LPC a C18:1 in ketamine-treated mice. These increases could be anti-inflammatory and/or could indicate increased mitochondrial oxidative capacity, given that LPCs are precursors for cardiolipin [84]. The large reduction in FA 18:2 plasma levels in ketamine-treated healthy volunteers may also have anti-inflammatory effects by reducing the availability of FA 18:2 metabolism to arachidonic acid [85].

Several PCs contributed positively to PC2 in the CSF of healthy volunteers. In the mouse arm of the study, several PCs increased following either and/or both treatments in plasma, with several of the PCs circulating in mouse plasma containing a saturated FA; in our study, this was predominantly eicosanoic acid. The changes in PC levels may have resulted from the remodeling of the PC species, a combination of effect on phospholipidase and/or acyltransferase activity [78], consistent with a study reporting that ketamine affected phospholipase activity [86]. A similar increase in PC levels was observed after treatment with the SSRIs, citalopram and escitalopram [78]. An increase in circulating concentrations of ether-phospholipids was also observed, which is believed to be beneficial because reduced levels of ether-lipids reduce brain levels of various neurotransmitters [87]. Interestingly, in the hypothalamus, PC ae C36:5 decreased following either ketamine or (2,6,8)-HNK treatment, and PC aa C36:6 also decreased following (2,6,8)-HNK treatment. A reduction in the relative abundance of several PC species in the prefrontal cortex of rats was found after administration of the antidepressants maprotiline and paroxetine [82, 88]. Paroxetine also increased levels of cholesterol and TGs, whereas fluoxetine decreased cholesterol and TG levels [89]. In our study, most TGs were elevated following ketamine treatment in the plasma of healthy volunteers. While a similar observation was made in ketamine-treated mice for three TGs, four TGs were decreased in (2,6,8)-HNK-treated mice, demonstrating possible distinct effects of (2,6,8)-HNK and ketamine and suggesting differential mechanisms.

Similar metabolomic changes between treatments could be attributed to the metabolism of ketamine to (2,6,8)-HNK, while treatment-specific changes could help elucidate the mechanism of action underlying both ketamine and (2,6,8)-HNK. In addition to the treatment-specific changes discussed above, in comparative analysis between ketamine and (2,6,8)-HNK, ketamine-treated mice also had decreased circulating levels of the excitatory amino acid neurotransmitters glutamate and aspartate, indicating NMDA-R dependent effects. However, similar effects were not observed in (2,6,8)-HNK treated mice, where increased circulating levels of serotonin were noted instead. The changes in circulating metabolite levels, as well as region-specific changes in the brain, suggest a different mechanism of action for (2,6,8)-HNK than ketamine. Notably, however, the region-specific changes are consistent with recent reports demonstrating that metabolite concentrations differ selectively in discrete regions of the brain [90, 91].

The present study has several strengths. In particular, participants were drug-free prior to the experiment, and the corresponding CSF and plasma were collected from each participant at multiple timepoints, and with minimum invasiveness after the initial intrathecal catheter insertion. Furthermore, the mouse arm of the study, carried out in parallel, offered insight into the contribution of (2,6,8)-HNK to the changes in the ketamine metabolome. Nevertheless, the study is also associated with several limitations, particularly the limited sample size. In addition, ketamine’s effects on healthy volunteers may differ from what would be observed in a patient sample. Finally, because this was an exploratory study, there is the possibility of Type I error (see rationale for analytic plan in the Supplementary Materials); future prospective studies should evaluate the replicability of the conclusions drawn from these results.
CONCLUSION
Inflammation has been associated with the pathogenesis of MDD [34, 92]. The present study demonstrated that ketamine and/or (2R,6R)-HNK affect multiple pathways associated with inflammatory conditions (Fig. 3). Interestingly, circulating plasma levels of the metabolites did not always mirror circulating CSF levels, suggesting compartmental-specific changes between plasma and CSF. Furthermore, region-selective differences in metabolite concentrations were observed in the hippocampus and/or hypothalamus of mice. Several metabolic changes following ketamine treatment were unique to either the healthy human volunteer and/or the mouse arm of the study; thus suggesting that different pathways may be differentially involved in ketamine’s antidepressant effects. Understanding such interconnections may be important for improving our understanding of the pathophysiology of depression as well as for refining new therapeutic strategies. Nevertheless, it should be noted that several aspects were consistent between the human metabolome in plasma and CSF and the mouse arm of the study; these include the potential roles of LAT1, IDO1, NAD+, the NO signaling pathway, and sphingolipid rheostat in the mechanisms underlying ketamine’s and/or (2R,6R)-HNK’s mechanism of action (Fig. 3). Future studies may wish to explore the role of LAT1 inhibitors, IDO1 inhibitors, and NAMPT inhibitors on the effects of ketamine and/or (2R,6R)-HNK.

REFERENCES
1. Dundee JW, Knox JW, Black GW, Moore J, Pandit SK, Bovill J, et al. Ketamine as an induction agent in anaesthetics. Lancet. 1970;1:1370–1.
2. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–4.
3. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NH, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–64.
4. Zarate CA Jr, Brutsche NH, Laje G, Luckenbaugh DA, Venkata SLV, Ramamoorthy A, et al. Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 2012;72:331–38.
5. Chong C, Schug SA, Page-Sharp M, Jenkins B, Illet KF. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study. Clin Drug Investig. 2009;29:317–24.
6. Goldberg ME, Torjan MC, Schwartzman RJ, Mager DE, Wainer IW. Pharmacodynamic profiles of ketamine (R)- and (S)- with 5-day inpatient infusion for the treatment of complex regional pain syndrome. Pain Physician. 2010;13:379–87.
7. Moaddel R, Venkata SLV, Tanga MJ, Bupp JE, Green CE, Iyer L, et al. A parallel randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. J Am Med Assoc. 2018;320:202.
8. Pradhan B, Mitre L, Moaddel R, Wainer IW. d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study. Biochim Biophys Acta. 2018;1866:631–9.
9. Clements JA, Jano W. Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth. 1981;53:27–30.
10. Royblat L, Talmor D, Rachinsky M, Greemberg L, Pekar A, Appelbaum A, et al. Ketamine attenuates the interleukin-6 response after cardiopulmonary bypass. Anesth Analg. 1998;87:266–71.
11. Krystal JH, Karpf LR, Seibyl JP, Freeman GK, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry. 1994;51:199–214.
12. Morgan CJ, Curran HV. Independent Scientific Committee on Drugs. Ketamine use: A review. Addiction. 2012;107:27–38.
13. Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharm Rev. 2018;70:621–60.
disease for participants of varying functional disability: A pilot study. Sci Rep. 2020 https://doi.org/10.1038/s41598-020-75726-9.
2. Lautrup S, Sinclair DA, Mattsson MP, Fang EF. NAD+ in brain aging and neurodegenerative disorders. Cell Metab. 2019;30:630–55.
3. Zukunft S, Prehn C, Röhring C, Möller G, Haberbosch W, Adamski J, et al. High-throughput extraction and quantification method for targeted metabolomics of urine samples. Metabolomics 2018 https://doi.org/10.1007/s11306-017-1312-x.
4. Westbrook R, Chung T, Lovett J, Coda W, Yang H, et al. Kynurenines link chronic inflammation to functional decline and physical frailty. JCI Insight. 2020 https://doi.org/10.1172/jci.insight.136091.
5. Wassertein RL, Schirm AL, Lazar NA. Moving to a world beyond “p < 0.05.” American Stat. 2019 https://doi.org/10.1080/00031305.2019.1583913.
6. Ima IS, Guarente L. NAD and ATP: Partners in immune cell modulation. Purinergic Signal. 2018 https://doi.org/10.1007/s11285-017-0557-2.
7. Hwang ES, Song SB. Possible adverse effects of high-dose nicotinamide: A systematic review and meta-analysis. J Psychopharmacol. 2021;35:124–7.
ACKNOWLEDGEMENTS
This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (IRP-NIA-NIH-ZIA000297-08), National Institute of Mental Health (IRP-NIMH-NIH; ZIAMHH002927; NCT03065335), and National Center for Advancing Translational Sciences. The work was also supported by VA Merit Awards 101BX004062 and 101BX003631-01A1 and NIH grants R01MH107615 and R21AI145211-01A1 to TDG. The authors thank Ioline Henter (NIMH-NIH) for invaluable editorial assistance.

AUTHOR CONTRIBUTIONS
RM, PZ, TG, and CAZ contributed to the study design. BK, EA, GWC, PY, MY, and LTP were involved in recruiting and collecting patient samples. PZ and TG were involved in collecting samples for the rodent studies. RM and JL were involved in data acquisition and pre-processing. CF was involved in creation of the analytic plan, data processing, data, and statistical analysis. CF, RM, and CAZ were involved in interpretation of the results. RM drafted the manuscript and all authors participated in critically revising and contributing to the final manuscript. We sincerely thank the participants in the 7SE research unit.

FUNDING
Open Access funding provided by the National Institutes of Health (NIH).

COMPETING INTERESTS
Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation. Drs. Zarate and Moaddel are co-inventors on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydroxynorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain. Drs. Zarate, Moaddel, Gould, Zanos, Morris, and Thomas are co-inventors on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders, and crystal forms and methods of synthesis of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine. Drs. Morris and Thomas are co-inventors on a patent application for the salts of (2R,6R)-hydroxynorketamine, their crystal forms, and methods of making the same and the process for synthesis and purification of (2R,6R)-hydroxynorketamine. Drs. Zarate, Moaddel, Morris, and Thomas have assigned their patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. Drs. Gould and Zanos have assigned their patent rights to the University of Maryland, Baltimore but will share a percentage of any royalties that may be received by the University of Maryland, Baltimore. All other authors have no conflict of interest to disclose, financial or otherwise.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41398-022-01941-x.

Correspondence and requests for materials should be addressed to Ruin Moaddel.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022